SavedAdd your journal

Journals / Afyon Kocatepe Üniversitesi İktisadi ve İdari Bilimler Fakültesi Dergisi / 2026 / Cilt: 9 Sayı: 1

Cilt. IX - Sayı 1 Haziran 2007

Pages
—
Publication Date
2007-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

Anonim (2007). Cilt. IX - Sayı 1 Haziran 2007. Afyon Kocatepe Üniversitesi İktisadi ve İdari Bilimler Fakültesi Dergisi, Cilt: 9 Sayı: 1. https://ajindex.com/articles/1060787

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (38)

  1. Esterly NA. Markovvitz M. The treatment of pyoderma in children. JAM A 1970; 212: 1667-1670.
  2. Barton LL, Friedman AD. İmpetigo: a reassessment of etiology and therapy. Pediatr Dermatol 1987; 4: 185-8.
  3. Dagan R. İmpetigo in childhood: Changing epidemiology and new treatments. Pediatr Ann 1993; 22: 235-240.
  4. Misko ML, Terracina )R, Diven DC. The frequency of erythromycin-resistant Staphylococcus aureus in impetiginized dermatoses. Pediatr Dermatol 1995; 12:12-5.
  5. Nishijima S, Nakagavva M. Sensitivity of antibacterials of Staphylococcus aureus isolated from impetigo patients. J Int Med Res 1997; 25:210-3.
  6. Jarvinen H, Nissinen A, Houvinen P. Erythromycin resistance in group A streptococci. Lancet 1989; 1: 1022-3.
  7. Leyden JJ. Mupirocin: a nevv topical antibiotic. Semin Dermatol 1987; 1: 48-54.
  8. Hughes J, Mellovvs C. O n the rnode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J Antibiot 1978; 31: 330-5.
  9. VVard A, Campoli-Richards DM. Mupirocin: A revievv of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986; 32: 425-44.
  10. Buchvald J. An evaluation of topical mupirocin in moderately severe primary and secondary skin infections. J Int Med Res 1988; 16: 66-70.
  11. VVuite J, Davies Bl, G o M, Lambers J, Jackson D, Mellovvs G. Pseudomonic acid, a nevv topical antimicrobial agent. Lancet 1983; 8346(ii): 394.
  12. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: Implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1992; 36: 287-90.
  13. Rice TD, Duggan AK, DeAngelis C. Cost-effectiveness of erythromycin versus mupirocin for the treatment of impetigo in children. Pediatrics 1992; 89: 210-4.
  14. Mertz PM, Marshall DA, Eaglstein WH, Piovanetti Y, Montalvo J. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol 1989; 125: 1069-73.
  15. I 5. McLinn S. A bacteriologically controlled, randomized study comparing the efficacy of 2 % mupirocin ointment (Bactroban) vvith oral erythromycin in the treatment of patients vvith impetigo. J Am Acad Dermatol 1990; 22: 883-5.
  16. Britton JW, Fajardo ]E, Crafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr 1990; 117(5): 827-9.
  17. Dux PH, Fields L, Pollock D. 2 % topical mupirocin versus systemic erythromycin and cloxacillin in primary and secondary skin infections. Curr Ther Res 1986; 40: 933-40.
  18. Arredondo JL. Efficacy and tolerance of topical mupirocin compared vvith oral dicloxacillin in the treatment of primary skin infections. Curr Ther Res 1987; 41: 121- 7.
  19. Bass JW, Chan DS, Creamer KM, Thompson MVV, Malone FJ, Becker TM, Marks SN. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J 1997; 16: 708- 10.
  20. VVelsh O, Saenz C. Topical mupirocin compared vvith oral ampicillin in the treatment of primary and secondary skin infections. Curr Ther Res 1 987; 41:114-20.
  21. Eells LD, Merts PM, Piovanetti Y, Pekoe GM, Eaglestein W H. Topical antibiotic treatment of impetigo vvith mupirocin. Arch Dermatol 1986; 122: 1273-6.
  22. Gilbert M. Topical 2 % mupirocin versus 2 % fusidic acid ointment in the treatment of primary and secondary skin infections. J A m Acad Dermatol 1989; 20: 1083- 7.
  23. VVhite DG, Collins PO, Rovvsell RB. Topical antibiotics in the treatment of superficial skin infections in general practice-a comparison of of mupirocin and sodium fıı- sidate. J Infect 1989; 18: 221-9.
  24. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol 1992; 31: 1-9.
  25. Leyden JJ. Revievv of mupirocin ointment in the treatment of impetigo. Clin Pediatr (Phila) 1992; 31(9): 549-53.
  26. Bork K, Brauers J, Kreşken M. Efficacy and safety of 2 % mupirocin ointment in the treatment of primary and secondary skin infeetions-an open multicenter trial. Br | Clin Prac 1989; 43: 284-8.
  27. Orecchio RM, Mischler TW. A double-blind multiclinic comparative trial of mupirocin topical and its vehicle in the treatment of bacterial skin infections. Curr Ther Res 1986; 39: 82-6.
  28. Sultan N, Çağlar K. Mupirosinin koagülaz pozitif ve negatif stafilokok suşlanna in-vitro etkisi. ANKE M Derg 1993; 7(2): 57.
  29. Koşan E, Kocabeyoğlu O, Keskin K, Özperçin i, Birinci i, Fidan A. Mupirosinin stafilokok, streptokok ve Enterococcus faecalis suşlarına etkinliğinin mikrodilüsyon yöntemiyle araştırılması. ANKE M Derg 1995; 9(1): 17- 9.
  30. Kaya D, Kaptanoğlu S, Kiraz N, Kaya E. Mupirosin (pseudomonic acid)'in yara örneklerinden izole edilen stafilokok suşlarına karşı in-vitro etkinliği. ANKE M Derg 1994; 8(2): 102.
  31. Barton LL, Friedman AD. İmpetigo: a reassessment of etiology and therapy. Pediatr Dermatol 1987; 4: 185-8.
  32. VVard A, Campoli-Richards DM. Mupirocin: A revievv of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986; 32: 425-44.
  33. Mertz PM, Marshall DA, Eaglstein WH, Piovanetti Y, Montalvo J. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol 1989; 125: 1069-73.
  34. Britton JW, Fajardo ]E, Crafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr 1990; 117(5): 827-9.
  35. Bass JW, Chan DS, Creamer KM, Thompson MVV, Malone FJ, Becker TM, Marks SN. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J 1997; 16: 708- 10.
  36. Eells LD, Merts PM, Piovanetti Y, Pekoe GM, Eaglestein W H. Topical antibiotic treatment of impetigo vvith mupirocin. Arch Dermatol 1986; 122: 1273-6.
  37. VVhite DG, Collins PO, Rovvsell RB. Topical antibiotics in the treatment of superficial skin infections in general practice-a comparison of of mupirocin and sodium fıı- sidate. J Infect 1989; 18: 221-9.
  38. Orecchio RM, Mischler TW. A double-blind multiclinic comparative trial of mupirocin topical and its vehicle in the treatment of bacterial skin infections. Curr Ther Res 1986; 39: 82-6.